MASATAKA KUWANA

Objective:Outcome of COVID-19 patients improved over the pandemic, i ncludi ngpatients with systemic rheumatic diseases. However, data on systemic sclerosis (SSc)patients are lacking. Th is study aimed to assess the outcome of SSc patients withCOV ID-19 over several waves. Methods:SSc patients with COVID-19 registered in...

Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice. Methods We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were...